Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.

Sliwa JK, Fu DJ, Bossie CA, Turkoz I, Alphs L.

BMC Psychiatry. 2014 Feb 22;14:52. doi: 10.1186/1471-244X-14-52.

2.

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW.

JAMA Psychiatry. 2015 Aug;72(8):830-9. doi: 10.1001/jamapsychiatry.2015.0241.

PMID:
25820612
3.

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

Li H, Rui Q, Ning X, Xu H, Gu N.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8. doi: 10.1016/j.pnpbp.2011.02.001. Epub 2011 Feb 18.

PMID:
21315787
4.

A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.

Coppola D, Liu Y, Gopal S, Remmerie B, Samtani MN, Hough DW, Nuamah I, Sulaiman A, Pandina G.

BMC Psychiatry. 2012 Mar 28;12:26. doi: 10.1186/1471-244X-12-26.

5.
6.

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D.

J Psychopharmacol. 2011 May;25(5):685-97. doi: 10.1177/0269881110372817. Epub 2010 Jul 8.

PMID:
20615933
7.

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS.

JAMA. 2014 May 21;311(19):1978-87. doi: 10.1001/jama.2014.4310. Erratum in: JAMA. 2014 Oct 8;312(14):1473.

8.

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M.

Int J Neuropsychopharmacol. 2010 Jun;13(5):635-47. doi: 10.1017/S1461145709990988. Epub 2009 Nov 27.

PMID:
19941696
9.

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M.

Schizophr Res. 2010 Feb;116(2-3):107-17. doi: 10.1016/j.schres.2009.10.026. Epub 2009 Dec 2.

PMID:
19959339
10.

Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.

De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU.

CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000. Review.

PMID:
22900950
11.

Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.

Fu DJ, Bossie CA, Sliwa JK, Ma YW, Alphs L.

Int Clin Psychopharmacol. 2014 Jan;29(1):45-55. doi: 10.1097/YIC.0000000000000006.

PMID:
24113628
12.

A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.

Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, Remmerie B, Eerdekens M.

Int J Neuropsychopharmacol. 2012 Feb;15(1):107-18. doi: 10.1017/S1461145711001076. Epub 2011 Jul 22. Erratum in: Int J Neuropsychopharmacol. 2012 Feb;15(1):119. Dosage error in article text.

PMID:
21777507
13.

Paliperidone palmitate for schizophrenia.

Nussbaum AM, Stroup TS.

Cochrane Database Syst Rev. 2012 Jun 13;(6):CD008296. doi: 10.1002/14651858.CD008296.pub2. Review.

PMID:
22696377
14.

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE).

Kozma CM, Slaton T, Dirani R, Fastenau J, Gopal S, Hough D.

Curr Med Res Opin. 2011 Aug;27(8):1603-11. doi: 10.1185/03007995.2011.595000. Epub 2011 Jun 22.

PMID:
21696265
15.

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.

Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, Yuen E, Hough D.

Neuropsychopharmacology. 2010 Sep;35(10):2072-82. doi: 10.1038/npp.2010.79. Epub 2010 Jun 16.

16.

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.

Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW.

Int Clin Psychopharmacol. 2010 Sep;25(5):247-56. doi: 10.1097/YIC.0b013e32833948fa.

PMID:
20389255
18.

Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.

Fu DJ, Bossie CA, Kern Sliwa J, Ma YW, Alphs L.

Clin Schizophr Relat Psychoses. 2014 Jul;8(2):101-9, 109A. doi: 10.3371/CSRP.FUBO.022213.

PMID:
23446197
19.

Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.

Schreiner A, Niehaus D, Shuriquie NA, Aadamsoo K, Korcsog P, Salinas R, Theodoropoulou P, Fernández LG, Uçok A, Tessier C, Bergmans P, Hoeben D.

J Clin Psychopharmacol. 2012 Aug;32(4):449-57. doi: 10.1097/JCP.0b013e31825cccad. Erratum in: J Clin Psychopharmacol. 2012 Dec;32(6):803.

PMID:
22722501
20.

A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.

Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J.

J Clin Psychopharmacol. 2010 Jun;30(3):235-44. doi: 10.1097/JCP.0b013e3181dd3103. Erratum in: J Clin Psychopharmacol. 2010 Aug;30(4):364.

PMID:
20473057

Supplemental Content

Support Center